{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:45:48Z","timestamp":1759365948732,"version":"build-2065373602"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14985-1","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:49:29Z","timestamp":1759315769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Suguru","family":"Kojima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironao","family":"Hozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"2","key":"14985_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0885-3924(00)00159-7","volume":"20","author":"JA Roscoe","year":"2000","unstructured":"Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage. 2000;20(2):113\u201321.","journal-title":"J Pain Symptom Manage"},{"issue":"23","key":"14985_CR2","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"6","key":"14985_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist. 2015;20(6):576\u201383.","journal-title":"Oncologist"},{"issue":"5","key":"14985_CR4","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015;20(5):855\u201365.","journal-title":"Int J Clin Oncol"},{"issue":"14","key":"14985_CR5","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356\u201367.","journal-title":"N Engl J Med"},{"key":"14985_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00019","volume":"8","author":"BL Rapoport","year":"2017","unstructured":"Rapoport BL. Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front Pharmacol. 2017;8:19.","journal-title":"Front Pharmacol"},{"key":"14985_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol. 2016;99:13\u201336.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"14985_CR8","first-page":"73","volume":"28","author":"H Woopen","year":"2020","unstructured":"Woopen H, Richter R, Chekerov R, Inci G, Alavi S, Grabowski JP, et al. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Support Care Cancer. 2020;28(1):73\u20138.","journal-title":"Support Care Cancer"},{"issue":"24","key":"14985_CR9","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14985_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024;9(2):102195.","journal-title":"ESMO Open"},{"issue":"31","key":"14985_CR11","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189\u201398.","journal-title":"J Clin Oncol"},{"issue":"6","key":"14985_CR12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015;26(6):1081\u201390.","journal-title":"Ann Oncol"},{"issue":"7","key":"14985_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2024","unstructured":"Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, et al. NCCN Guidelines\u00ae Insights Antiemesis, Version 22017 Featured Updates to the NCCN Guidelines. J Natl Compr Canc Ne. 2024;15(7):883\u201393.","journal-title":"J Natl Compr Canc Ne."},{"issue":"4","key":"14985_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bjc.2013.400","volume":"109","author":"M Tanioka","year":"2013","unstructured":"Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer. 2013;109(4):859\u201365.","journal-title":"Br J Cancer"},{"issue":"3","key":"14985_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","volume":"84","author":"Y Ito","year":"2014","unstructured":"Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer. 2014;84(3):259\u201364.","journal-title":"Lung Cancer"},{"issue":"3","key":"14985_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","volume":"90","author":"H Kusagaya","year":"2015","unstructured":"Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, et al. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer. 2015;90(3):410\u20136.","journal-title":"Lung Cancer"},{"issue":"8","key":"14985_CR17","first-page":"4527","volume":"35","author":"M Maehara","year":"2015","unstructured":"Maehara M, Ueda T, Miyahara D, Takahashi Y, Miyata K, Nam SO, et al. Clinical Efficacy of Aprepitant in Patients with Gynecological Cancer after Chemotherapy Using Paclitaxel and Carboplatin. Anticancer Res. 2015;35(8):4527\u201334.","journal-title":"Anticancer Res"},{"issue":"27","key":"14985_CR18","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"14985_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12032-017-0937-y","volume":"34","author":"N Inui","year":"2017","unstructured":"Inui N. Antiemetic therapy for non-anthracycline and cyclophosphamide moderately emetogenic chemotherapy. Med Oncol. 2017;34(5):77.","journal-title":"Med Oncol"},{"issue":"2","key":"14985_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87\u201396.","journal-title":"Neuropsychopharmacology"},{"key":"14985_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejphar.2013.08.048","volume":"722","author":"RM Navari","year":"2014","unstructured":"Navari RM. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014;722:180\u20136.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"14985_CR22","first-page":"1655","volume":"21","author":"RM Navari","year":"2013","unstructured":"Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21(6):1655\u201363.","journal-title":"Support Care Cancer"},{"issue":"11","key":"14985_CR23","first-page":"1285","volume":"15","author":"RM Navari","year":"2007","unstructured":"Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15(11):1285\u201391.","journal-title":"Support Care Cancer"},{"key":"14985_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1756-9966-28-131","volume":"28","author":"L Tan","year":"2009","unstructured":"Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28:131.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"14985_CR25","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/SPC.0000000000000206","volume":"10","author":"SM Bosnjak","year":"2016","unstructured":"Bosnjak SM, Dimitrijevic J, Djordjevic F. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine. Curr Opin Support Palliat Care. 2016;10(2):180\u20138.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"7","key":"14985_CR26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bcp.13242","volume":"83","author":"T Yang","year":"2017","unstructured":"Yang T, Liu Q, Lu M, Ma L, Zhou Y, Cui Y. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis. Br J Clin Pharmacol. 2017;83(7):1369\u201379.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"14985_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134\u201342.","journal-title":"N Engl J Med"},{"issue":"2","key":"14985_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(2):242\u20139.","journal-title":"Lancet Oncol"},{"key":"14985_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101771","volume":"55","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Yang Y, Gao F, Hu C, Zhong D, Lu M, et al. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine. 2023;55:101771.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"14985_CR30","first-page":"2381","volume":"24","author":"L Chiu","year":"2016","unstructured":"Chiu L, Chow R, Popovic M, Navari RM, Shumway NM, Chiu N, et al. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016;24(5):2381\u201392.","journal-title":"Support Care Cancer"},{"issue":"1","key":"14985_CR31","first-page":"45","volume":"32","author":"F Scotte","year":"2023","unstructured":"Scotte F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh PJ, et al. 2023 updated MASCC\/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer. 2023;32(1):45.","journal-title":"Support Care Cancer"},{"issue":"1","key":"14985_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","volume":"84","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol. 2019;84(1):147\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"14985_CR33","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.24.00278","volume":"42","author":"N Inui","year":"2024","unstructured":"Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, et al. Olanzapine plus triple antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting: a randomized, double-blind, placebo-controlled phase III trial. J Clin Oncol. 2024;42(23):2780\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14985_CR34","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","volume":"25","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayashi T, Kawazoe H, Saeki T, Aiba K, et al. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan. Oncologist. 2020;25(2):e373\u201380.","journal-title":"Oncologist"},{"issue":"5","key":"14985_CR35","first-page":"444","volume":"17","author":"A Molassiotis","year":"2008","unstructured":"Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA. Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care (Engl). 2008;17(5):444\u201353.","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"14","key":"14985_CR36","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.22.01997","volume":"41","author":"L Sandhya","year":"2023","unstructured":"Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, et al. Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol. 2023;41(14):2617\u201327.","journal-title":"J Clin Oncol"},{"issue":"8","key":"14985_CR37","doi-asserted-by":"publisher","first-page":"e2426076","DOI":"10.1001\/jamanetworkopen.2024.26076","volume":"7","author":"V Ostwal","year":"2024","unstructured":"Ostwal V, Ramaswamy A, Mandavkar S, Bhargava P, Naughane D, Sunn SF, et al. Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial. JAMA Netw Open. 2024;7(8):e2426076.","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"14985_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000227648","volume":"53","author":"IN Olver","year":"1996","unstructured":"Olver IN. Antiemetic study methodology: recommendations for future studies. Oncology. 1996;53(Suppl 1):96\u2013101.","journal-title":"Oncology"},{"issue":"3","key":"14985_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","volume":"156","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M, et al. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study. Gynecol Oncol. 2020;156(3):629\u201335.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"14985_CR40","doi-asserted-by":"publisher","first-page":"e1066","DOI":"10.1002\/onco.13772","volume":"26","author":"C Sakai","year":"2021","unstructured":"Sakai C, Shimokawa M, Iihara H, Fujita Y, Ikemura S, Hirose C, et al. Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial. Oncologist. 2021;26(6):e1066\u201372.","journal-title":"Oncologist"},{"issue":"9","key":"14985_CR41","first-page":"1171","volume":"18","author":"PJ Hesketh","year":"2010","unstructured":"Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18(9):1171\u20137.","journal-title":"Support Care Cancer"},{"issue":"6","key":"14985_CR42","first-page":"807","volume":"19","author":"DG Warr","year":"2011","unstructured":"Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. 2011;19(6):807\u201313.","journal-title":"Support Care Cancer"},{"issue":"1","key":"14985_CR43","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1186\/s12885-021-08572-3","volume":"21","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Iihara H, Uozumi R, Kawazoe H, Tanaka K, Fujita Y, et al. Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. BMC Cancer. 2021;21(1):832.","journal-title":"BMC Cancer"},{"key":"14985_CR44","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2147\/CMAR.S370961","volume":"14","author":"M Shimokawa","year":"2022","unstructured":"Shimokawa M, Haratake N, Takada K, Toyokawa G, Takamori S, Mizuki F, et al. Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy. Cancer Manag Res. 2022;14:2673\u201380.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"14985_CR45","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"14985_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07802-y","volume":"21","author":"T Hayashi","year":"2021","unstructured":"Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T, et al. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021;21(1):74.","journal-title":"BMC Cancer"},{"issue":"2","key":"14985_CR47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1470-2045(23)00628-9","volume":"25","author":"J Bajpai","year":"2024","unstructured":"Bajpai J, Kapu V, Rath S, Kumar S, Sekar A, Patil P, et al. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2024;25(2):246\u201354.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14985-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:03:32Z","timestamp":1759320212000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14985-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14985"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14985-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Studies were performed in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and the study protocols were approved by the institutional review board of Hamamatsu University School of Medicine (approval numbers: 16\u2013296 and 19\u2013120). Informed consent was obtained from all individual participants included in both studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1494"}}